Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
- Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a single AAV vector- Two poster presentations describe methods that support accelerated development of Arbor’s proprietary gene editing platform CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announces the presentation of data demonstrating the fir